3-beta-hydroxy-5-alpha-pregnan-20-one for use in medical treatment
The present invention provides the steroid compound 3beta-hydroxy-5alpha-pregnan-20-one for use in treatment of Tourette's syndrome, obsessive compulsive disorder and/or gambling disorder, as well as methods for treating said disorders and pharmaceutical compositions for use in treatment of said disorders.
1. A method of treating Tourette's syndrome, obsessive compulsive disorder and/or gambling disorder, comprising administering a pharmaceutically effective amount of 3beta-hydroxy-5alpha-pregnan-20-one, to a patient in need thereof.
2. The method according to claim 1 , wherein the patient suffers from Tourette's syndrome, and 3beta-hydroxy-5alpha-pregnan-20-one is administered in an amount effective to treat the patient's Tourette's syndrome.
3. The method according to claim 1 , wherein the patient suffers from obsessive compulsive disorder, and 3beta-hydroxy-5alpha-pregnan-20-one is administered in an amount effective to treat the patient's obsessive-compulsive disorder.
4. The method according to claim 1 , wherein the patient suffers from gambling disorder, and 3beta-hydroxy-5alpha-pregnan-20-one is administered in an amount effective to treat the patient's gambling disorder.
5. The method according to claim 1 , wherein 3beta-hydroxy-5alpha-pregnan-20-one is administered in combination with at least one additional active compound, selected from the group consisting of serotonin reuptake inhibitors (SSRI), 5alpha-reducase blockers, typical and atypical neuroleptics, antihypertensive agents, tricyclic antidepressants, and opioid antagonists.
6. The method according to claim 5 wherein the serotonin reuptake inhibitors (SSRI) are selected from the group consisting of citalopram, ecitalopram, fluoxetine, sertraline, and fluvoxamine.
7. The method according to claim 5 wherein the 5alpha-reducase blockers are selected from the group consisting of finasteride or dutasteride.
8. The method according to claim 1 , wherein the 3beta-hydroxy-5alpha-pregnan-20-one is administered in a pharmaceutical composition comprising 3beta-hydroxy-5alpha-pregnan-20-one and one or more pharmaceutically acceptable carriers, excipients and/or diluents.
9. The method according to claim 5 , wherein the typical and atypical neuroleptics are selected from the group consisting of risperdone, ziprasidone, haloperidol, pimozide and fluphenazine.
10. The method according to claim 5 , wherein the antihypertensive agents are selected from the group consisting of clonidine and guanfacine.
11. The method according to claim 5 , wherein the tricyclic antidepressant is clomipramine.
12. The method according to claim 1 , wherein said 3beta-hydroxy-5-alpha-pregnan-20-one is administered intravenously, nasally, buccally, vaginally, rectally, subcutaneously, percutaneously or orally.
13. The method according to claim 1 , wherein said 3beta-hydroxy-5-alpha-pregnan-20-one is administered topically, locally, orally, parenterally or pulmonary.
14. The method according to claim 1 , wherein the 3beta-hydroxy-5-alpha-pregnan-20-one is in the form of a pharmaceutically acceptable salt, sulphate or ester.